Diagnostic Use of Post-therapy 131I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma

123I-meta-iodobenzylguanidine (123I-mIBG) scintigraphy is used for evaluating disease extent in children with neuroblastoma. 131I-mIBG therapy has been used for evaluation in children with high-risk neuroblastoma, and post-therapy...

Full description

Bibliographic Details
Main Authors:	Hiroshi Wakabayashi, Daiki Kayano, Anri Inaki, Raita Araki, Rie Kuroda, Norihito Akatani, Takafumi Yamase, Satoru Watanabe, Tomo Hiromasa, Yuji Kunita, Hiroshi Mori, Shintaro Saito, Yasuhiro Ikawa, Toshihiro Fujiki, Seigo Kinuya
Format:	Article
Language:	English
Published:	MDPI AG 2020-09-01
Series:	Diagnostics
Subjects:	diagnostic <sup>123</sup>I-mIBG scintigraphy post-therapeutic <sup>131</sup>I-mIBG scintigraphy high-risk neuroblastoma consolidation therapy
Online Access:	https://www.mdpi.com/2075-4418/10/9/663

id	doaj-66f78a23b1f946638aa7f886539e7062
record_format	Article
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Hiroshi Wakabayashi Daiki Kayano Anri Inaki Raita Araki Rie Kuroda Norihito Akatani Takafumi Yamase Satoru Watanabe Tomo Hiromasa Yuji Kunita Hiroshi Mori Shintaro Saito Yasuhiro Ikawa Toshihiro Fujiki Seigo Kinuya
spellingShingle	Hiroshi Wakabayashi Daiki Kayano Anri Inaki Raita Araki Rie Kuroda Norihito Akatani Takafumi Yamase Satoru Watanabe Tomo Hiromasa Yuji Kunita Hiroshi Mori Shintaro Saito Yasuhiro Ikawa Toshihiro Fujiki Seigo Kinuya Diagnostic Use of Post-therapy <sup>131</sup>I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma Diagnostics diagnostic <sup>123</sup>I-mIBG scintigraphy post-therapeutic <sup>131</sup>I-mIBG scintigraphy high-risk neuroblastoma consolidation therapy
author_facet	Hiroshi Wakabayashi Daiki Kayano Anri Inaki Raita Araki Rie Kuroda Norihito Akatani Takafumi Yamase Satoru Watanabe Tomo Hiromasa Yuji Kunita Hiroshi Mori Shintaro Saito Yasuhiro Ikawa Toshihiro Fujiki Seigo Kinuya
author_sort	Hiroshi Wakabayashi
title	Diagnostic Use of Post-therapy <sup>131</sup>I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma
title_short	Diagnostic Use of Post-therapy <sup>131</sup>I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma
title_full	Diagnostic Use of Post-therapy <sup>131</sup>I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma
title_fullStr	Diagnostic Use of Post-therapy <sup>131</sup>I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma
title_full_unstemmed	Diagnostic Use of Post-therapy <sup>131</sup>I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma
title_sort	diagnostic use of post-therapy <sup>131</sup>i-meta-iodobenzylguanidine scintigraphy in consolidation therapy for children with high-risk neuroblastoma
publisher	MDPI AG
series	Diagnostics
issn	2075-4418
publishDate	2020-09-01
description	<sup>123</sup>I-meta-iodobenzylguanidine (<sup>123</sup>I-mIBG) scintigraphy is used for evaluating disease extent in children with neuroblastoma. <sup>131</sup>I-mIBG therapy has been used for evaluation in children with high-risk neuroblastoma, and post-therapy <sup>131</sup>I-mIBG scintigraphy may detect more lesions compared with diagnostic <sup>123</sup>I-mIBG scintigraphy. However, no studies have yet revealed the detection rate of hidden mIBG-avid lesions on post-therapy <sup>131</sup>I-mIBG whole-body scan (WBS) and SPECT images in neuroblastoma children without mIBG-avid lesions as demonstrated by diagnostic <sup>123</sup>I-mIBG scintigraphy. We retrospectively examined the diagnostic utility of post-therapy <sup>131</sup>I-mIBG scintigraphy in children who received <sup>131</sup>I-mIBG as consolidation therapy. Nineteen children with complete response to primary therapy were examined. Post-therapy <sup>131</sup>I-mIBG scintigraphy was performed four days after injection. The post-therapy <sup>131</sup>I-mIBG scintigraphy, 4 children exhibited abnormal uptake on the WBS. Post-therapy <sup>131</sup>I-mIBG SPECT/CT provided additional information in 2 cases. In total, 6 children exhibited abnormal uptake. The site of abnormal accumulation was on the recurrence site in one case, operation sites in five cases, and bone metastasis in one case. Post-therapy <sup>131</sup>I-mIBG scintigraphy could detect residual disease that was not recognized using diagnostic <sup>123</sup>I-mIBG scintigraphy in 32% of children with high-risk neuroblastoma and ganglioneuroblastoma. The diagnostic use of post-therapy <sup>131</sup>I-mIBG scintigraphy can provide valuable information for detecting residual disease.
topic	diagnostic <sup>123</sup>I-mIBG scintigraphy post-therapeutic <sup>131</sup>I-mIBG scintigraphy high-risk neuroblastoma consolidation therapy
url	https://www.mdpi.com/2075-4418/10/9/663
work_keys_str_mv	AT hiroshiwakabayashi diagnosticuseofposttherapysup131supimetaiodobenzylguanidinescintigraphyinconsolidationtherapyforchildrenwithhighriskneuroblastoma AT daikikayano diagnosticuseofposttherapysup131supimetaiodobenzylguanidinescintigraphyinconsolidationtherapyforchildrenwithhighriskneuroblastoma AT anriinaki diagnosticuseofposttherapysup131supimetaiodobenzylguanidinescintigraphyinconsolidationtherapyforchildrenwithhighriskneuroblastoma AT raitaaraki diagnosticuseofposttherapysup131supimetaiodobenzylguanidinescintigraphyinconsolidationtherapyforchildrenwithhighriskneuroblastoma AT riekuroda diagnosticuseofposttherapysup131supimetaiodobenzylguanidinescintigraphyinconsolidationtherapyforchildrenwithhighriskneuroblastoma AT norihitoakatani diagnosticuseofposttherapysup131supimetaiodobenzylguanidinescintigraphyinconsolidationtherapyforchildrenwithhighriskneuroblastoma AT takafumiyamase diagnosticuseofposttherapysup131supimetaiodobenzylguanidinescintigraphyinconsolidationtherapyforchildrenwithhighriskneuroblastoma AT satoruwatanabe diagnosticuseofposttherapysup131supimetaiodobenzylguanidinescintigraphyinconsolidationtherapyforchildrenwithhighriskneuroblastoma AT tomohiromasa diagnosticuseofposttherapysup131supimetaiodobenzylguanidinescintigraphyinconsolidationtherapyforchildrenwithhighriskneuroblastoma AT yujikunita diagnosticuseofposttherapysup131supimetaiodobenzylguanidinescintigraphyinconsolidationtherapyforchildrenwithhighriskneuroblastoma AT hiroshimori diagnosticuseofposttherapysup131supimetaiodobenzylguanidinescintigraphyinconsolidationtherapyforchildrenwithhighriskneuroblastoma AT shintarosaito diagnosticuseofposttherapysup131supimetaiodobenzylguanidinescintigraphyinconsolidationtherapyforchildrenwithhighriskneuroblastoma AT yasuhiroikawa diagnosticuseofposttherapysup131supimetaiodobenzylguanidinescintigraphyinconsolidationtherapyforchildrenwithhighriskneuroblastoma AT toshihirofujiki diagnosticuseofposttherapysup131supimetaiodobenzylguanidinescintigraphyinconsolidationtherapyforchildrenwithhighriskneuroblastoma AT seigokinuya diagnosticuseofposttherapysup131supimetaiodobenzylguanidinescintigraphyinconsolidationtherapyforchildrenwithhighriskneuroblastoma
_version_	1724628662768107520
spelling	doaj-66f78a23b1f946638aa7f886539e70622020-11-25T03:18:08ZengMDPI AGDiagnostics2075-44182020-09-011066366310.3390/diagnostics10090663Diagnostic Use of Post-therapy <sup>131</sup>I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk NeuroblastomaHiroshi Wakabayashi0Daiki Kayano1Anri Inaki2Raita Araki3Rie Kuroda4Norihito Akatani5Takafumi Yamase6Satoru Watanabe7Tomo Hiromasa8Yuji Kunita9Hiroshi Mori10Shintaro Saito11Yasuhiro Ikawa12Toshihiro Fujiki13Seigo Kinuya14Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, JapanDepartment of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, JapanDepartment of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, JapanDepartment of Pediatrics, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, JapanDepartment of Pediatrics, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, JapanDepartment of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, JapanDepartment of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, JapanDepartment of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, JapanDepartment of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, JapanDepartment of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, JapanDepartment of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, JapanDepartment of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, JapanDepartment of Pediatrics, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, JapanDepartment of Pediatrics, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, JapanDepartment of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, Japan<sup>123</sup>I-meta-iodobenzylguanidine (<sup>123</sup>I-mIBG) scintigraphy is used for evaluating disease extent in children with neuroblastoma. <sup>131</sup>I-mIBG therapy has been used for evaluation in children with high-risk neuroblastoma, and post-therapy <sup>131</sup>I-mIBG scintigraphy may detect more lesions compared with diagnostic <sup>123</sup>I-mIBG scintigraphy. However, no studies have yet revealed the detection rate of hidden mIBG-avid lesions on post-therapy <sup>131</sup>I-mIBG whole-body scan (WBS) and SPECT images in neuroblastoma children without mIBG-avid lesions as demonstrated by diagnostic <sup>123</sup>I-mIBG scintigraphy. We retrospectively examined the diagnostic utility of post-therapy <sup>131</sup>I-mIBG scintigraphy in children who received <sup>131</sup>I-mIBG as consolidation therapy. Nineteen children with complete response to primary therapy were examined. Post-therapy <sup>131</sup>I-mIBG scintigraphy was performed four days after injection. The post-therapy <sup>131</sup>I-mIBG scintigraphy, 4 children exhibited abnormal uptake on the WBS. Post-therapy <sup>131</sup>I-mIBG SPECT/CT provided additional information in 2 cases. In total, 6 children exhibited abnormal uptake. The site of abnormal accumulation was on the recurrence site in one case, operation sites in five cases, and bone metastasis in one case. Post-therapy <sup>131</sup>I-mIBG scintigraphy could detect residual disease that was not recognized using diagnostic <sup>123</sup>I-mIBG scintigraphy in 32% of children with high-risk neuroblastoma and ganglioneuroblastoma. The diagnostic use of post-therapy <sup>131</sup>I-mIBG scintigraphy can provide valuable information for detecting residual disease.https://www.mdpi.com/2075-4418/10/9/663diagnostic <sup>123</sup>I-mIBG scintigraphypost-therapeutic <sup>131</sup>I-mIBG scintigraphyhigh-risk neuroblastomaconsolidation therapy

Diagnostic Use of Post-therapy <sup>131</sup>I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma

Similar Items